Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07325916

Relationship Between Serum Apolipoprotein Levels and Weight Loss in Patients Undergoing Sleeve Gastrectomy for Morbid Obesity

The study looks at whether a specific protein in the blood, called apolipoprotein, can predict how much weight a person might lose after sleeve gastrectomy, a surgery for people with severe obesity. We want to find a specific level of this protein that shows which patients are most likely to lose weight successfully after surgery. By identifying this level, we hope to guide doctors in deciding who should have the surgery and who might do better with non-surgical weight loss methods.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Morbid Obesity Requiring Bariatric Surgery Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity, Morbid Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Basaksehir Cam and Sakura City Hospital

Istanbul, Basaksehir, 34480, Turkey (Türkiye)

About this study

The subject of our research is whether serum apolipoprotein levels can be a predictive value for weight loss in patients who will undergo sleeve gastrectomy due to morbid obesity. Our aim is to determine a cut-off value for patients who benefit most from bariatric surgery based on preoperative serum apolipoprotein levels. By including this value among the surgical indications, we plan to direct patients less likely to benefit from surgery to conservative approaches.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 to 75
  • International Classification of Diseases (ICD) code E66 diagnosis (obesity)
  • Patients who have given consent for sleeve gastrectomy
  • Patients who are suitable for general anesthesia

Exclusion criteria

  • Patients who did not give consent to be included in the study
  • Patients who are scheduled for surgery other than sleeve gastrectomy

Treatment and study plan

Laparoscopic sleeve gastrectomy

Procedure

Laparoscopic Sleeve Gastrectomy

Primary outcomes

  1. Change in body mass index at 8 months

    Time frame: 8 months after surgery

Secondary outcomes

  1. Change in lipid profile at 8 months

    Time frame: 8 months after surgery

Sponsors and collaborators

Lead sponsor

Yigit DUZKOYLU

Other Gov

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 8, 2026
Registry last updated
Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.